Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2021

View Archived Issues

Alethia studies AB-16B5 with docetaxel in phase II for metastatic NSCLC

Beth Israel Deaconess Medical Center presents anti-Tn antibodies

Janssen R&D Ireland divulges new antituberculous compounds

ER-alpha antagonists and SERDs patented by Sanofi

Bayer discovers BCAT1/2 ihibitors

HBV HBeAg and HBsAg secretion inhibitors identified at Roche

Acylaminooxadiazoles inhibit trans-translation and show in vivo efficacy against N. gonorrhoeae

A new knock-in mouse model related to spinocerebellar ataxia 14

Harpoon Therapeutics develops FLT3-targeting TriTACs for treating acute myeloid leukemia

CD161 linked to outcomes in head and neck cancer patients

NX-1607 targets E3 ubiquitin-protein ligase CBL-B for antitumor immunotherapy

Aurigene details preclinical activity of anticancer compounds AU-18069 and AU-19820

Soticlestat reduces frequency of seizures in pediatric patients with DS and LGS

Autophagy chaperone targets aggregation-prone proteins

FDA removes clinical hold on IND application for VY-HTT01

Promising phase II data presented for olamkicept in ulcerative colitis

First patient enrolled in phase IIa study of CM-101 in NASH

Roflumilast demonstrates cognition-enhancing effects in patients with schizophrenia

Reviva reports strong phase II data in schizophrenia

Neoleukin to proceed with phase I study of NL-201 in the U.S.

FDA removes clinical hold on uniQure's hemophilia B gene therapy program

Cybin targets IND filing for CYB-003 for alcohol use disorder by year-end

CoA Therapeutics initiates phase I study of BBP-671

FYB-207 advancing towards clinical trials for COVID-19 in fourth quarter

SciClone evaluates COVID-19 inactivated vaccine with Zadaxin in China

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
SKL-35501 shows broad antitumor activity in solid tumors
BioWorld Science
Neurotensin receptor 1 (NTSR1) is overexpressed in several aggressive solid tumors, including colorectal and pancreatic cancer, making it a promising therapeutic...